Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Jupiter Neurosciences Inc (JUNS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.13-13.41%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for JUNS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve positive EPS | Analysts expect a small positive EPS of $0.06 in 2026. | Intact | EPS falls below $0.00 in FY26 | Diluted EPS: $-4.08 per share FY2026-Q2; GAAP. Published target: EPS >= $0.06 in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-4.08 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story, not an established earnings compounder. The thesis is on watch: management has repeatedly named the ALA-002 program as a priority, but financial delivery remains limited and confidence in the evidence is low.
The evidence snapshot provides no valuation multiple or clear account of market expectations, so valuation cannot be assessed reliably. Persistent losses and listing-compliance concerns are visible risks, while the stronger Healthcare sector backdrop is a potential support rather than proof of business progress.
Near term, ongoing operating losses, negative cash flow, and elevated risk of an earnings miss leave fundamentals fragile. Management has acted on listing compliance with a reverse stock split, but the company remains under Nasdaq review; efforts to manage losses have so far shown limited progress.
Over the next one to three years, the thesis hinges on whether JUNS can advance its plan to acquire and develop exclusive U.S. rights to ALA-002 while controlling losses. Near-term sector support could strengthen if healthcare bellwethers keep reporting strong results, but weaker employment data or setbacks at those companies could deepen pressure on cyclical healthcare names.
JUNS has a narrow, execution-dependent multi-year view, with persistent losses and listing concerns outweighing the sector tailwind for now. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It is pursuing new drug licensing deals. |
| Under Pressure |
| No meaningful licensing progress by FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Address Nasdaq listing compliance issues | Jupiter Neurosciences is working to fix Nasdaq compliance issues. | Under Pressure | Nasdaq issues remain unresolved past FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.” Delivery assessment Nov 5, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.26 → $-19.50 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-07-25 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-07-26 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-07-27 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-07-28 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-07-29 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-07-30 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-07-31 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-01 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-02 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-03 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-04 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-05 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-06 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-07 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-08 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-09 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-10 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-12 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-13 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-14 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-15 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-16 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-17 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-18 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-19 | $-0.26 | $7,358,000 | 1 / 1 |
| 2026-08-20 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-21 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-22 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-23 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-24 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-25 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-26 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-27 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-28 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-29 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-30 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-08-31 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-01 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-02 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-03 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-04 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-05 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-06 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-07 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-08 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-09 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-10 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-11 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-12 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-13 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-14 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-15 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-16 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-17 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-18 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-19 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-20 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-21 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-22 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-23 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-24 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-25 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-26 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-27 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-28 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-29 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-09-30 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-01 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-02 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-03 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-04 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-05 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-06 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-07 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-08 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-09 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-10 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-11 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-12 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-13 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-14 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-15 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-16 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-17 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-18 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-19 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-20 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-21 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-22 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-23 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-24 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-25 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-26 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-27 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-28 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-29 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-30 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-10-31 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-11-01 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-11-02 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-11-03 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-11-04 | $-19.50 | $7,358,000 | 1 / 1 |
| 2026-11-05 | $-19.50 | $7,358,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.